Medeon Biodesign (6499) — Capital Reinvestment Ratio

Latest as of March 2022: 0.68x

Medeon Biodesign (6499) has a Capital Reinvestment Ratio of 0.68x as of March 2022, meaning it reinvests 1% of its operating cash flow (NT$60.74 Million) in capital expenditures (NT$41.12 Million). Check tangible equity quality of Medeon Biodesign to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.68x
Capex / Operating Cash Flow

Operating Cash Flow

NT$60.74 Million
TWD

Capital Expenditures

NT$41.12 Million
TWD

Data as of

Mar 2022
Most recent filing

Medeon Biodesign Capital Reinvestment Ratio (2018–2018)

This chart tracks Medeon Biodesign's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see Medeon Biodesign (6499) cash conversion ratio.

Annual Capital Reinvestment Ratio for Medeon Biodesign (2018–2018)

Year-by-year Capital Reinvestment Ratio for Medeon Biodesign from 2018 to 2018. See 6499 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (TWD) Capital Expenditures YoY Change
2018 0.16x NT$322.05 Million NT$51.14 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow